Physician profile
Ginger Webb
NPI 1770990061
$9,117.80
in general payments reported to CMS, 2019-2025
35 companies · $963 in 2025
The $963 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,245 · 2022: $1,749 · 2023: $2,226 · 2024: $1,936 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,060 · Education: $64.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,059.78 |
| Education | $64.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,774.13 | 2021-2025 | |
| Pfizer INC. | $685.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $629.06 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $565.68 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $479.74 | 2021-2025 | Trintellix |
| Amgen INC. | $457.62 | 2021-2025 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $440.29 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.06 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $421.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $395.43 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $381.03 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $335.49 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.01 | 2021-2025 | Relistor, Xifaxan, Trulance |
| Grifols USA, LLC | $210.98 | 2021-2025 | Prolastin-C Liquid |
| Kowa Pharmaceuticals America, INC. | $173.15 | 2021-2024 | Livalo, Seglentis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $161.25 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $152.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $144.66 | 2021-2023 | |
| Daiichi Sankyo INC. | $144.12 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $142.20 | 2021 | |
| Redhill Biopharma INC. | $114.44 | 2021-2022 | |
| Exact Sciences Corporation | $86.56 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $83.77 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.53 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $58.55 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $54.18 | 2023 | Quviviq |
| Optinose US, INC. | $51.52 | 2021 | |
| Impel Pharmaceuticals INC. | $44.22 | 2022-2023 | Trudhesa |
| Verona Pharma, INC. | $36.39 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.40 | 2023 | Lifevest |
| Teva Pharmaceuticals USA, INC. | $23.36 | 2021 | |
| Axsome Therapeutics, INC. | $22.98 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $21.80 | 2021 | |
| Ardelyx, INC. | $14.60 | 2024 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.